Nona Biosciences and ModeX Therapeutics partner for antibodies discovery
24 May 2023
Preview
Source: Pharmaceutical Technology
The collaboration is expected to shorten the preclinical antibody therapeutics development process. Credit: SAMUEL GABRIEL from Pixabay.
HBM’s wholly owned subsidiary Nona Biosciences has entered an agreement with OPKO Health’s ModeX Therapeutics for the discovery of antibodies.
ModeX Therapeutics will gain access to the fully human Harbour Mice platforms of Nona Bioscience for integration into its MSTAR platform to expedite the monoclonal antibodies’ discovery.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsInnovation in Pharmaceuticals: Affinity chromatography for antibodies GlobalData
Preview
Source: Pharmaceutical Technology
ReportsBiosimilars in Pharmaceuticals: Recombinant antibodies for cytotoxic T-cells GlobalData
View all
This is expected to significantly shorten the preclinical antibody therapeutics development process.
ModeX’s MSTAR platform has been designed to layer the multispecific functionality onto industry-standard antibody designs to enable a broad range of disease applicability and functionality.
It helps to quickly generate candidates that target up to six distinct biological pathways in one molecule.
The modular design of the platform enables quick testing of many combinations of antigen-binding domains for targeting multiple sites.
This maximises specificity and improves therapeutic efficacy while minimising off-target effects.
Nona Biosciences chairman Jingsong Wang stated: “We are delighted to enter into this collaboration with ModeX Therapeutics.
“We believe that our discovery platforms are highly complementary to ModeX’s approach and are pleased to be able to offer a solution with the potential to speed the discovery of antibodies that ModeX can leverage in multispecific research and development.”
The partnership aims to use the unique strengths of each company to drive the discovery of treatments.
ModeX chief scientific officer John Mascola stated: “We look forward to partnering with Nona Biosciences to accelerate and enhance our discovery of novel multispecific antibody constructs that our team can advance into clinical development”.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.